New data from the PROCLIPI study has shown a meaningful overall survival benefit for patients with advanced cutaneous T-cell ...

ENA Respiratory has raised US$22.4m (AU$34m) in Series B financing to support the phase 2 clinical development of its nasal spray therapy, INNA-051. The Melbourne-based pharmaceutical company welcomed ...

Nxera Pharma and its partner Cancer Research UK have presented encouraging results from the completed phase 1 portion of ...

The Global Fund has welcomed a £6 million joint investment from GSK and ViiV Healthcare to strengthen community-led responses ...

Janssen-Cilag International NV, part of Johnson & Johnson, has announced encouraging results from the phase 1b/2 OrigAMI-4 ...

Adocia and Tonghua Dongbao have announced positive topline results from a phase 3 clinical trial of BioChaperone Lispro ...

The National Institute for Health and Care Research (NIHR) has announced a £157 million investment over 5 years to support 10 ...

AstraZeneca’s Saphnelo (anifrolumab) has received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) for approval in the European Union as a self-administered, ...

Artificial intelligence tools that could revolutionise patient care are being trialled in phase 2 of the Medicines and ...

Eligible patients in Scotland with relapsed or refractory multiple myeloma will now have access to a new treatment option ...

Women in Scotland suffering from endometriosis now have access to a new treatment option following the Scottish Medicines ...

AbbVie has announced new clinical data from its antibody-drug conjugate (ADC) platform, reinforcing its commitment to ...